Twelve patients found to be colonized with C. difficile will undergo twice a day potato starch supplementation.

Clostridium Difficile

Hematologic Diseases

Potato starch will be given twice a day for up to 14 days, discharge, or death, whichever occurs first.

Potato starch

Medical College of Wisconsin

Oligosaccharide for Cdiff(+) Heme-onc Patients

Oligosaccharide Supplementation Among Hematology-Oncology Clostridium Difficile Colonized Patients

Samples will be collected twice a week (4-5 times during supplementation) and one time at day 21 or discharge, whichever happens first.

Patients will be provided with a diary in which they will document compliance with oligosaccharide intake. It is anticipated ≥70% of intended doses to be fully administered by the patient.

It is expected ≥50% of stool samples to be correctly collected and processed.

Stool samples collected for diagnosis and any additional stool collections will be thawed in batches and one cc aliquot will be extracted refreezing the remaining sample at -80 degrees F. One cc aliquot will then be divided into 4 sub-samples of equal volume and with the same unique identifier. This identifier will be able to chronologically cluster samples by each unique patient. A sample will be used for C. difficile qPCR quantitative determination.

Sub-sample of stool from diagnosis, and additional stool collections will be used for 16S ribosomal ribonucleic acid gene sequencing to determine the microbiome community structure

Siliva Munoz-Price

Professor

Treatment with study medication twice daily for 2 weeks (from study visit 1 to study visit 2)

Treatment with placebo twice daily for 2 weeks (from study visit 1 to study visit 2)

Vaginal Infection

Pregnancy Complications

Neonatal Sepsis

oral intake of Astarte® (HSO Health Care GmbH, Vienna, Austria) as described

Astarte® (HSO Health Care GmbH, Vienna, Austria)

Identical-looking oral potato-maltodextrin-based placebo

Placebo

Medical University of Vienna, Vienna General Hospital, Department of Obstetrics and Gynecology

Oral Probiotics to Reduce Vaginal Group B Streptococcal Colonization in Late Pregnancy

Oral Probiotics to Reduce Vaginal Group B Streptococcal Colonization in Late Pregnancy: A Randomized Placebo-controlled Double-blinded Trial

Eradication of vaginal colonization with group B Streptococcus (GBS) at study visit 2

Rate of early-onset and/or late-onset neonatal sepsis

Term delivery at or after 37 + 0 gestational weeks vs. preterm delivery at or before 36 + 6 gestational weeks

sepsis/patates

Oligosaccharide for Cdiff(+) Heme-onc Patients

Oral Probiotics to Reduce Vaginal Group B Streptococcal Colonization in Late Pregnancy

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı